Es-Citalopram for the prevention of PEG-IFN-α and Ribavirin associated depression in HCV-infected patients without psychiatric risk factors (CIPPAD-study)
M Schäfer, R Sarkar, U Spengler, T Schlaepfer, J Ockenga, A Friebe, S Effenberger, L Heinze, P Buggisch, J Reimer, R Link, B Hintsche, V Weich, F van Boemmel, S Zeuzem, T Berg · Zeitschrift für Gastroenterologie · 2009 · Heft 01
Bibliografische Angaben
Zusammenfassung
Objective: The „EsCItalopram for the Prevention of PEGASYSΘ Associated Depression study“ (CIPPAD-study) is a prospective multicentre, randomized, double-blind, placebo-controlled clinical trial with the primary objective to evaluate the impact of a 2-week antidepressant pretreatment with Escitalopram on the incidence and severity of interferon-alpha associated depression. Study design: Patients without any history of psychiatric or substance abuse disorder either received escitalopram 10mg/day 2 weeks prior to commencement of HCV therapy and or received placebo. All patients were treated with pegylated interfero…
